Telesis Bio, Inc. (TBIO)

Market Cap	1.10B
Revenue (ttm)	27.44M
Net Income (ttm)	-48.47M
Shares Out	29.56M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	201,050
Open	37.64
Previous Close	37.36
Day's Range	2.91 - 3.32
52-Week Range	12.50 - 37.99
Beta	n/a
Analysts	Buy
Price Target	5.36 (+72.9%)
Earnings Date	May 9, 2023

About TBIO

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building bloc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 212
• Stock Exchange: NASDAQ
• Ticker Symbol: TBIO

Financial Performance

In 2022, Telesis Bio's revenue was $27.44 million, an increase of 148.44% compared to the previous year's $11.04 million. Losses were -$48.47 million, 24.4% more than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for TBIO stock is "Buy." The 12-month stock price forecast is $5.36, which is an increase of 72.90% from the latest price.

Price Target

$5.36

(72.90% upside)

Analyst Consensus: Buy